Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this first-in-human study, BLZ-100, an intraoperative fluorescent imaging agent, was administered to 21 patients before skin cancer surgery and was found to be well tolerated without serious adverse effects, suggesting its potential to help distinguish cancerous from non-cancerous tissue based on fluorescence.

In this study, Nd:YAG picosecond lasers using fractional micro-lens array were found to have a comparable effect to ablative fractional Er:YAG lasers in treating atrophic acne scars, with better safety profiles but slightly less patient satisfaction.

In this study, QR 678 and QR 678 Neo formulations containing growth factors and peptides were found to be safe in vitro and promoted hair growth in vivo in an animal model, suggesting their potential as treatments for alopecia, including secondary alopecia post-chemotherapy.

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

This study suggests that the DNMT3B -579 G>T polymorphism may be a genetic risk factor for colorectal cancer in the Azerbaijani population.

This study successfully cloned the KAP6.1 gene from Xinjiang fine-wool sheep and found its genetic sequence has high homology with sheep and goat sequences, indicating close genetic relationships.

In this multicenter Phase II trial, researchers found that topical GT20029 significantly increased hair regrowth in Chinese adult males with androgenetic alopecia compared to placebo, demonstrating good tolerability and suggesting the need for further studies to confirm its therapeutic potential.

This study found that chromosomal microarray analysis identified copy number variations in 12% of patients with dysmorphic features and congenital anomalies, demonstrating its potential as a diagnostic tool, especially for rare CNVs and immune deficiency linked to the deletion of CTLA4.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

This study concluded that the topical gel VB1953 reduced inflammatory and non-inflammatory acne lesions and resistant bacteria in patients with clindamycin-resistant acne, showing promise as an effective treatment.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

This study identified two novel mutations in the CDH3 gene causing HJMD in a Chinese patient, expanding the genetic and phenotypic understanding of the disorder.

This Phase II trial found that topical GT20029 significantly increased hair count and width at 12 weeks in Chinese men with androgenetic alopecia compared to placebo, with good tolerability and similar adverse event incidence across groups.

This report documents a novel alanine to valine substitution in the GJB2 gene in a Japanese girl with severe keratitis–ichthyosis–deafness syndrome, suggesting a potential link to her severe recurrent infections and immunodeficiency.

In this study, the researchers found distinct patterns of TGF-beta 1 and IGF-II expression in pig fetal subcutaneous tissue, suggesting specific regulatory roles in developing adipocytes and muscle tissue.

This study reported the first case of a NIPAL4 c.527C>A mutation in Romanian patients with autosomal recessive congenital ichthyosis, finding that NIPAL4 mutations are more common than TGM1 mutations in this population.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

This case report describes a 12-year-old boy with severe skin scaling due to novel compound heterozygous null truncation mutations in the TGM1 gene, resulting in loss of transglutaminase 1 activity.